Deals and Partnerships

Amylyx Secures Series A Financing for Phase II Trial in ALS

Cambridge, MA-based Amylyx Pharmaceuticals Inc. announced that it has secured a $5M Series A financing round to support its Phase II trial of AMX0035 in ALS.  The trial will test efficacy of this combination drug of sodium phenylbutyrate (PB) and tauroursodeoxycholic acid (TUDCA), both of which have individually been tested in ALS clinical trials, and have shown efficacy in […]

Read more »


NeuroBANK™ Program to be Expanded With Large Grant

The NeuroBANK™ program at the Neurological Clinical Research Institute (NCRI) has received $3.6M in funding from The ALS Association, Massachusetts General Hospital (MGH), and ALS Finding A Cure  to support its expansion over the next 3 years. NeuroBANK is a patient-centric clinical research platform that facilitates integration of information across research projects, and provides core services for clinical […]

Read more »


Yumanity and NY Stem Cell Foundation Announce Discovery Collaboration

Yumanity Therapeutics, a biotechnology company focused on drug discovery for neurodegenerative diseases associated with protein misfolding, has announced a partnership with the NY Stem Cell Foundation (NYSCF) Research Institute to generate induced pluripotent stem cell (iPSC) lines for applications in drug discovery for ALS, Alzheimer’s and Parkinson’s disease (see Feb 2016 news). Yumanity will leverage NYSCF’s […]

Read more »


Target ALS Selects RUDCR Infinite Biologics for ALS Stem Cell Core

The Target ALS Foundation has contracted with Rutgers University Cell and DNA Repository (RUCDR) Infinite Biologics, a unit of Rutgers’ Human Genetics Institute of New Jersey and the largest university-based biorepository, to house the human ALS stem cell lines of the Target ALS stem cell core. The available cell lines from at RUDCR can be […]

Read more »